Safety of Antidiabetic Therapies on Bone

摘要: Osteoporosis and diabetic disease have reached epidemic proportion create significant public health concerns. The prevalence of these diseases is alarming indicates that in the United States, 50% elderly individuals are osteoporotic almost 20% population has either or prediabetic conditions (Centers for Disease Control Prevention; http://www.cdc.gov). diabetes share many features including genetic predispositions molecular mechanisms. linkage between two chronic diseases, which stems from overlapping controls involved bone homeostasis energy metabolism, creates a possibility certain antidiabetic therapies may affect bone. This concurs with recent findings, indicating status closely linked to regulation metabolism insulin sensitivity. Indeed, under control same regulatory factors, insulin, peroxisome proliferator-activated receptor gamma, gastrointestinal hormones such as glucose inhibitory protein glucagon peptide, bone-derived hormone osteocalcin. These factors related mechanisms fatty acid fat tissue, pancreas, intestine, pharmacological targets therapies. contribute quality by their effect on cell differentiation remodeling process. implies should be considered vital target modulate metabolism. review summarizing available data skeletal effects clinically approved